Blue Jet Healthcare IPO: Is It Worth Subscribing?
Blue Jet Healthcare's IPO has opened for subscription, and it's making quite a buzz in the financial world. But should you jump on the bandwagon? Let's take a closer look.
IPO Details
The Blue Jet Healthcare IPO is open for public subscription until Friday, October 27, 2023. The price band for the public issue ranges from Rs 329 to Rs 346 per equity share with a face value of Rs 2 each. At the upper end of this price band, the company's promoters and shareholders aim to raise a substantial Rs 840.27 crore through the IPO. It's worth noting that the IPO is an offer-for-sale (OFS), with promoters selling 24,285,160 shares of Rs 2 each, aggregating to Rs 840.27 crore.
Growing Market Premium (GMP)
Before the IPO even hit the market, the Grey Market Premium (GMP) for Blue Jet Healthcare shares rose to an impressive 18.21%. This suggests strong early investor interest in the company.
What Does Blue Jet Healthcare Do?
Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredients and intermediates company, focusing on niche products aimed at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
The company operates a contract development and manufacturing organization (CDMO) business model with specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. These capabilities have been developed through strategic investments in research & development as well as manufacturing infrastructure.
The company produces a range of products in-house, including key starting intermediate and advanced intermediates, allowing them to maintain control over production processes for consistent quality and cost-effectiveness.
Expert Opinions
Several financial experts have weighed in on whether you should subscribe to the Blue Jet Healthcare IPO.
Here's what they had to say:
Choice Broking:
They recommend subscribing to the IPO, highlighting the company's strong growth prospects, sustained demand for its products, and lower/stabilizing raw material prices. They believe the company's valuation is reasonable.
Geojit:
Geojit suggests subscribing to the IPO on a medium- to long-term basis, considering the company's promising industry outlook and expansion plans.
Mehta Equities:
Mehta Equities also recommends subscribing to the IPO, acknowledging that the issue is fully priced but highlighting Blue Jet's unique niche product segment.
Stoxbox:
Stoxbox believes that Blue Jet Healthcare has a strong track record of growth and solid financial performance. They recommend subscribing to the IPO.
In conclusion, the Blue Jet Healthcare IPO seems to be generating significant interest, and the company has some promising aspects. However, it's crucial to do your research and consider your risk tolerance before investing.
Disclaimer
Remember that the advice given by these experts is just to inform you. Investing in stock market involves risks. So, it is suggested to talk to your investment experts before making any investment decisions.